Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series.

Front Oncol · 2022 · PMC9004604 · PMID 35425698

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similarly, results from the EMERGING-CTONG 1103 study showed a trend toward improved ORR, lymph node step-down, MPR, and R0 resection rates with neoadjuvant erlotinib compared to neoadjuvant chemotherapy for patients with EGFRm NSCLC, and significantly prolonged PFS ( 16 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.